Isolated hepatic perfusion for metastatic melanoma

Journal of Surgical Oncology

Volumn 109, Issue 4, 2014, Pages 383-388

  Yamamoto, Maki ^a   Zager, Jonathan S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

isolated hepatic perfusion; melphalan; percutaneous hepatic perfusion

Indexed keywords

ISOLATED HEPATIC PERFUSION; MELPHALAN; PERCUTANEOUS HEPATIC PERFUSION;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; HEPATIC ARTERY; HUMANS; LIVER NEOPLASMS; MELANOMA;

EID: 84893922859     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23474     Document Type: Review

References (37)

1. Siegel R, Naishadham D, Jemal A:, Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Balch CM, Soong SJ, Gershenwald JE, et al.: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634.
3. Leiter U, Meier F, Schittek B, et al.: The natural course of cutaneous melanoma. J Surg Oncol 2004; 86: 172-178.
4. Albert DM, Ryan LM, Borden EC:, Metastatic ocular and cutaneous melanoma: A comparison of patient characteristics and prognosis. Arch Ophthalmol 1996; 114: 107-108.
5. Balch CM, Gershenwald JE, Soong SJ, et al.: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
6. Pawlik TM, Zorzi D, Abdalla EK, et al.: Hepatic resection for metastatic melanoma: Distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 2006; 13: 712-720.
7. Hodi FS, O'Day SJ, McDermott DF, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
8. Chapman PB, Hauschild A, Robert C, et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
9. Singh AD, Turell ME, Topham AK:, Uveal melanoma: Trends in incidence, treatment, and survival. Ophthalmology 2011; 118: 1881-1885.
10. Rajpal S, Moore R, Karakousis CP:, Survival in metastatic ocular melanoma. Cancer 1983; 52: 334-336.
11. Jones A, Alexander HR, Jr:, Development of isolated hepatic perfusion for patients who have unresectable hepatic malignancies. Surg Oncol Clin N Am 2008; 17: 857-876, x.
12. Diener-West M, Reynolds SM, Agugliaro DJ, et al.: Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol 2005; 123: 1639-1643.
13. Kujala E, Makitie T, Kivela T:, Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44: 4651-4659.
14. Sato T, Babazono A, Shields JA, et al.: Time to systemic metastases in patients with posterior uveal melanoma. Cancer Invest 1997; 15: 98-105.
15. Gragoudas ES, Egan KM, Seddon JM, et al.: Survival of patients with metastases from uveal melanoma. Ophthalmology 1991; 98: 383-389, discussion 390.
16. Vauthey J-N:, Liver metastases. London: Springer; 2009.
17. Alexander HR, on behalf of the CS-PHP Investigators: Percutaneous hepatic perfusion (PHP or ChemoSat) with melphalan versus best alternative care (BAC) in patients (pts) with hepatic metastases from melanoma: A post hoc analysis of PHP-randomized versus BAC-to-PHP crossover versus BAC-only pts. ASCO Meet Abstr 2012; 30: 8570.
18. Pingpank JF, Hughes MS, Alexander HR, et al.: A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. ASCO Meet Abstr 2010; 28: LBA8512.
19. Pingpank JF, Libutti SK, Chang R, et al.: Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 2005; 23: 3465-3474.
20. Joiner MC, Steel GG, Stephens TC:, Response of two mouse tumours to hyperthermia with CCNU or melphalan. Br J Cancer 1982; 45: 17-26.
21. Gnant MF, Noll LA, Terrill RE, et al.: Isolated hepatic perfusion for lapine liver metastases: Impact of hyperthermia on permeability of tumor neovasculature. Surgery 1999; 126: 890-899.
22. Alexander HR, Jr, Bartlett DL, Libutti SK, et al.: Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998; 16: 1479-1489.
23. Rothbarth J, Pijl ME, Vahrmeijer AL, et al.: Isolated hepatic perfusion with high-dose melphalan for the treatment of colorectal metastasis confined to the liver. Br J Surg 2003; 90: 1391-1397.
24. Alexander HR, Jr, Butler CC:, Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases. Cancer J 2010; 16: 132-141.
25. Barker WC, Andrich MP, Alexander HR, et al.: Continuous intraoperative external monitoring of perfusate leak using iodine-131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med 1995; 22: 1242-1248.
26. Ausman RK:, Development of a technic for isolated perfusion of the liver. N Y State J Med 1961; 61: 3993-3997.
27. Alexander HR, Jr, Libutti SK, Pingpank JF, et al.: Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003; 9: 6343-6349.
28. Bartlett DL, Libutti SK, Figg WD, et al.: Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 2001; 129: 176-187.
29. Marinelli A, Vahrmeijer AL, van de Velde CJ:, Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases. Recent Results Cancer Res 1998; 147: 83-94.
30. Hafstrom LR, Holmberg SB, Naredi PL, et al.: Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol 1994; 3: 103-108.
31. Alexander HR, Libutti SK, Bartlett DL, et al.: A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2000; 6: 3062-3070.
32. Noter SL, Rothbarth J, Pijl ME, et al.: Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res 2004; 14: 67-72.
33. Rizell M, Mattson J, Cahlin C, et al.: Isolated hepatic perfusion for liver metastases of malignant melanoma. Melanoma Res 2008; 18: 120-126.
34. van Etten B, de Wilt JH, Brunstein F, et al.: Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases. Eur J Surg Oncol 2009; 35: 539-545.
35. Deneve JL, Choi J, Gonzalez RJ, et al.: Chemosaturation with percutaneous hepatic perfusion for unresectable isolated hepatic metastases from sarcoma. Cardiovasc Intervent Radiol 2012; 35: 1480-1487.
36. Ravikumar TS, Pizzorno G, Bodden W, et al.: Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol 1994; 12: 2723-2736.
37. Miao N, Pingpank JF, Alexander HR, et al.: Percutaneous hepatic perfusion in patients with metastatic liver cancer: Anesthetic, hemodynamic, and metabolic considerations. Ann Surg Oncol 2008; 15: 815-823.